Two-year results from a Swedish study on conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma – The ARTSCAN study
| Autor: | Britta Lödén, Lars Franzén, E. Persson, Anders Ask, Hans Modig, Gun Wickart-Johansson, Ove Björ, Claes Mercke, Lena Wittgren, Helena Sjödin, Elisabeth Kjellén, Per Nilsson, Eva Brun, Signe Friesland, Freddi Lewin, Karl-Axel Johansson, Thomas Björk-Eriksson, Jan-Olof Fernberg, Björn Zackrisson, Lars Ekberg, Jan Nyman, Johan Reizenstein |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Larynx medicine.medical_specialty medicine.medical_treatment Gastroenterology Accelerated fractionation Internal medicine medicine Clinical endpoint Humans Radiology Nuclear Medicine and imaging Aged Aged 80 and over Sweden Chemotherapy Squamous Cell Carcinoma of Head and Neck business.industry Head and neck cancer Hematology Middle Aged medicine.disease Head and neck squamous-cell carcinoma Surgery Radiation therapy Regimen medicine.anatomical_structure Oncology Head and Neck Neoplasms Carcinoma Squamous Cell Female Dose Fractionation Radiation Morbidity business |
| Zdroj: | Radiotherapy and Oncology. 100:41-48 |
| ISSN: | 0167-8140 |
| DOI: | 10.1016/j.radonc.2010.12.010 |
| Popis: | Background and purpose: Studies on accelerated fractionation (AF) in head and neck cancer have shown increased local control and survival compared with conventional fractionation (CF), while others have been non-conclusive. In 1998 a national Swedish group decided to perform a randomised controlled clinical study of AF. Materials and methods: Patients with verified squamous cell carcinoma of the oral cavity, oropharynx, larynx (except glottic T1 -T2, N0) and hypopharynx were included. Patients with prior chemotherapy or surgery were excluded. Patients were randomised to either CF (2 Gy/day, 5 days/week for 7 weeks, total dose 68 Gy) or to AF (1.1 Gy + 2.0 Gy/day, 5 days/week for 4.5 weeks, total dose 68 Gy). An extensive quality assurance protocol was followed throughout the study. The primary end point was loco-regional tumour control (LRC) at two years after treatment. Results: The study was closed in 2006 when 750 patients had been randomised. Eighty-three percent of the patients had stages III-IV disease. Forty eight percent had oropharyngeal, 21% laryngeal, 17% hypopharyngeal and 14% oral cancers. There were no significant differences regarding overall survival (OS) or LRC between the two regimens. The OS at two years was 68% for AF and 67% for CF. The corresponding figures for LRC were 71% and 67%, respectively. There was a trend towards improved LRC for oral cancers treated (p = 0.07) and for large tumours (T3-T4) (p = 0.07) treated with AF. The AF group had significantly worse acute reactions, while there was no significant increase in late effects. Conclusion: Overall the AF regimen did not prove to be more efficacious than CF. However, the trend towards improved results in AF for oral cancers needs to be further investigated. (c) 2011 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 100 (2011) 41-48 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect